These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 35207810)

  • 21. Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score.
    Feng C; Zhang Y; Wu F; Li J; Liu M; Lv W; Li C; Wang W; Tan Q; Xue X; Ma X; Zhang S
    Breast; 2023 Jun; 69():392-400. PubMed ID: 37116400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
    Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Velazquez C; Orhan E; Tabet I; Fenou L; Orsetti B; Adélaïde J; Guille A; Thézénas S; Crapez E; Colombo PE; Chaffanet M; Birnbaum D; Sardet C; Jacot W; Theillet C
    Front Oncol; 2023; 13():1125021. PubMed ID: 37007122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
    Masuda N; Bando H; Yamanaka T; Kadoya T; Takahashi M; Nagai SE; Ohtani S; Aruga T; Suzuki E; Kikawa Y; Yasojima H; Kasai H; Ishiguro H; Kawabata H; Morita S; Haga H; Kataoka TR; Uozumi R; Ohno S; Toi M
    Breast Cancer Res Treat; 2021 Jul; 188(1):117-131. PubMed ID: 33763789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis.
    Caramelo O; Silva C; Caramelo F; Frutuoso C; Pinto L; Almeida-Santos T
    Hered Cancer Clin Pract; 2022 Sep; 20(1):34. PubMed ID: 36085046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
    Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
    Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Li ZY; Zhang Z; Cao XZ; Feng Y; Ren SS
    J Int Med Res; 2020 Oct; 48(10):300060520964340. PubMed ID: 33100072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
    Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
    Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Zuo K; Yuan X; Liang X; Sun X; Liu S; Connell PP; Li X; Yang W
    Breast Cancer Res Treat; 2022 Jan; 191(2):335-344. PubMed ID: 34797456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
    Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
    Ter Brugge P; Moser SC; Bièche I; Kristel P; Ibadioune S; Eeckhoutte A; de Bruijn R; van der Burg E; Lutz C; Annunziato S; de Ruiter J; Masliah Planchon J; Vacher S; Courtois L; El-Botty R; Dahmani A; Montaudon E; Morisset L; Sourd L; Huguet L; Derrien H; Nemati F; Chateau-Joubert S; Larcher T; Salomon A; Decaudin D; Reyal F; Coussy F; Popova T; Wesseling J; Stern MH; Jonkers J; Marangoni E
    Nat Commun; 2023 Apr; 14(1):1958. PubMed ID: 37029129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
    Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
    BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies.
    Pokataev I; Fedyanin M; Polyanskaya E; Popova A; Agafonova J; Menshikova S; Tryakin A; Rumyantsev A; Tjulandin S
    ESMO Open; 2020; 5(1):e000578. PubMed ID: 33551067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
    J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
    Lenz L; Neff C; Solimeno C; Cogan ES; Abramson VG; Boughey JC; Falkson C; Goetz MP; Ford JM; Gradishar WJ; Jankowitz RC; Kaklamani VG; Marcom PK; Richardson AL; Storniolo AM; Tung NM; Vinayak S; Hodgson DR; Lai Z; Dearden S; Hennessy BT; Mayer EL; Mills GB; Slavin TP; Gutin A; Connolly RM; Telli ML; Stearns V; Lanchbury JS; Timms KM
    Breast Cancer Res Treat; 2023 Nov; 202(1):191-201. PubMed ID: 37589839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
    BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency.
    Yuan P; Ma N; Xu B
    Med Res Rev; 2024 Jun; ():. PubMed ID: 38922930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
    Yndestad S; Engebrethsen C; Herencia-Ropero A; Nikolaienko O; Vintermyr OK; Lillestøl RK; Minsaas L; Leirvaag B; Iversen GT; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Aase HS; Aas T; Gudlaugsson EG; Llop-Guevara A; Serra V; Janssen EAM; Lønning PE; Knappskog S; Eikesdal HP
    JCO Precis Oncol; 2023 Sep; 7():e2300338. PubMed ID: 38039432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic and epigenomic
    Menghi F; Banda K; Kumar P; Straub R; Dobrolecki L; Rodriguez IV; Yost SE; Chandok H; Radke MR; Somlo G; Yuan Y; Lewis MT; Swisher EM; Liu ET
    Sci Transl Med; 2022 Jul; 14(652):eabn1926. PubMed ID: 35857626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.